- Home
- ROIV vs CHRW Comparison
ROIV vs CHRW Comparison
Compare ROIV & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CHRW |
|---|---|---|
| Founded | 2014 | 1905 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 23.0B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CHRW |
|---|---|---|
| Price | $29.24 | $182.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | $28.94 | ★ $181.32 |
| AVG Volume (30 Days) | ★ 4.2M | 1.5M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | N/A | ★ 25.13 |
| EPS | N/A | ★ 4.83 |
| Revenue | $29,053,000.00 | ★ $14,869,380,000.00 |
| Revenue This Year | N/A | $5.07 |
| Revenue Next Year | $744.61 | $6.26 |
| P/E Ratio | ★ N/A | $38.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $86.58 |
| 52 Week High | $30.33 | $203.34 |
Technical Indicators
Market Signals| Indicator | ROIV | CHRW |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 60.85 |
| Support Level | $20.46 | $160.14 |
| Resistance Level | $30.33 | $194.54 |
| Average True Range (ATR) | 0.85 | 5.88 |
| MACD | 0.10 | 2.42 |
| Stochastic Oscillator | 74.72 | 83.30 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.